Treating diabetic lower extremity ulcers with vLPM and vCPM tissue allografts ‘improves mortality’, study finds

Using vLPM and vCPM allografts in the treatment of diabetic lower extremity ulcers is linked to improved outcomes when compared to using other cellular tissue products or standard of care, a study has found.

Researchers say the initial cost of using viable lyopreserved placental membrane (vLPM) allographs and viable cryopreserved placental membrane (vCPM) is “offset” by the long-term improvements in patient outcomes.

These improvements include reduced wound recurrence and amputation, along with improvements in overall mortality.

When standard of care (SOC) is used in the treatment of diabetic lower extremity ulcers, the five-year associated mortality rate ranges from 24.6% to over 40%. These low survival rates call for new treatment options for these patients.

Researchers from the University of Southern California, Los Angeles, studied data from patients with diabetic lower extremity ulcers or venous leg ulcers who were treated withvLPM, vCPM, or other cellular tissue products, or SOC between 2016 and 2020.

Treatment which resulted in amputation, mortality, or wound recurrence after a year was classed as an adverse outcome.

There were 333,362 episodes of diabetic lower extremity ulcers and 122,012 episodes of venous leg ulcersacross the study period.

At one year, for patients with diabetic lower extremity ulcers who were treated with vLPM, there was a reduction in mortality, wound recurrence, and adverse outcomes in comparison to patients who received SOC.

Additionally, this treatment was linked to reduced wound recurrence compared to other cellular tissue products.